Health19 hours ago
Corcept Therapeutics Secures “Buy” Rating with $134.50 Target Price
Corcept Therapeutics Incorporated (NASDAQ:CORT) has received a consensus rating of “Buy” from the five brokerage firms currently covering its stock, according to a report by Marketbeat...